Ignite Creation Date:
2025-12-24 @ 2:53 PM
Ignite Modification Date:
2025-12-26 @ 9:08 PM
Study NCT ID:
NCT01274559
Status:
TERMINATED
Last Update Posted:
2024-05-22
First Post:
2010-10-25
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-03-01
Start Date Type:
ACTUAL
Primary Completion Date:
2013-02-26
Primary Completion Date Type:
ACTUAL
Completion Date:
2013-02-26
Completion Date Type:
ACTUAL
First Submit Date:
2010-10-25
First Submit QC Date:
None
Study First Post Date:
2011-01-11
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2014-01-30
Results First Submit QC Date:
None
Results First Post Date:
2014-03-14
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-05-20
Last Update Post Date:
2024-05-22
Last Update Post Date Type:
ACTUAL